Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution-Reference-Cited by-同舟云学术

Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution

Published:2016-05-03 Issue:5 Volume:97 Page:479-488
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Franssen Laurens E.¹²,Raymakers Reinier A. P.¹,Buijs Arjan³,Schmitz Marian F.¹,van Dorp Suzanne⁴,Mutis Tuna²,Lokhorst Henk M.¹²,van de Donk Niels W. C. J.²

Affiliation:

1. Department of Hematology; University Medical Center Utrecht; Utrecht the Netherlands

2. Department of Hematology; VU University Medical Center; Amsterdam the Netherlands

3. Department of Genetics; University Medical Center Utrecht; Utrecht the Netherlands

4. Department of Hematology; Radboud University Medical Center; Nijmegen the Netherlands

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12758/fullpdf

Reference47 articles.

1. Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy;Coman;Haematologica,2013

2. The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation;Donato;Biol Blood Marrow Transplant,2014

3. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma;Kröger;Exp Hematol,2009

4. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma;Donk;Bone Marrow Transplant,2006

5. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma;Donk;Blood,2006

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years;Frontiers in Oncology;2024-07-31

2. Allogeneic Stem Cell Transplantation in Multiple Myeloma;Cancers;2021-12-23

3. CAR T-cell therapy for multiple myeloma: state of the art and prospects;The Lancet Haematology;2021-06

4. Long-term outcome after allogeneic stem cell transplantation in multiple myeloma;Annals of Hematology;2021-04-17

5. Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma;Biology of Blood and Marrow Transplantation;2020-11